Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 145.45 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $17.874 million which beat the analyst consensus estimate of $16.095 million by 11.06 percent. This is a 85.18 percent increase over sales of $9.652 million the same period last year.